Edition:
United Kingdom

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

26.58CNY
14 Feb 2018
Change (% chg)

¥0.07 (+0.26%)
Prev Close
¥26.51
Open
¥26.46
Day's High
¥26.94
Day's Low
¥26.31
Volume
2,384,634
Avg. Vol
8,101,593
52-wk High
¥31.87
52-wk Low
¥18.09

Chart for

About

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine... (more)

Overall

Beta: 0.80
Market Cap(Mil.): ¥23,372.63
Shares Outstanding(Mil.): 1,042.49
Dividend: 0.18
Yield (%): 0.80

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Zhejiang Huahai Pharmaceutical's Preliminary 2017 Net Profit Up 26.45 Pct Y/Y

* SAYS PRELIM 2017 NET PROFIT UP 26.45 PERCENT Y/Y AT 633.29 MILLION YUAN ($101.16 million) Source text in Chinese: http://bit.ly/2Bf04WM Further company coverage: ($1 = 6.2600 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

07 Feb 2018

BRIEF-Zhejiang Huahai Pharmaceutical says fire accident in unit's warehouse

* Says fire accident has occurred at a warehouse of co's Zhejiang-based wholly owned pharmaceutical unit, on Jan. 18

19 Jan 2018

BRIEF-Zhejiang Huahai Pharmaceutical to invest in pharma industry park project

* Says it plans to invest in pharma industry park project with total investment at about 10 billion yuan ($1.50 billion)

29 Oct 2017

BRIEF-Zhejiang Huahai Pharmaceutical passes U.S. FDA approval

* Says it received approval for a kind of tablet, which is used for treatment of chronic hepatitis B, from U.S. Food and Drug Administration

13 Oct 2017

BRIEF-Zhejiang Huahai Pharmaceutical passes FDA approval

* Says it received approval for its production base of API from U.S Food and Drug Administration

28 Sep 2017

BRIEF-Zhejiang Huahai Pharmaceutical to use $30 mln to acquire shares of Eutilex

* Says co signs agreement to invest $30 million in Eutilex Co.,Ltd, which is mainly engaged in R&D of T cell therapy and antibody therapy products

05 Sep 2017

BRIEF-Zhejiang Huahai Pharmaceutical passes U.S. FDA approval

* Says it received FDA approval for Paroxetine Capsules from U.S Food and Drug Administration

22 Aug 2017

Earnings vs. Estimates